...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells
【24h】

Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells

机译:单细胞RNA-SEQ揭示了一种不同的单倍性造血细胞的转录组特征

获取原文
获取原文并翻译 | 示例

摘要

Cancer cells frequently exhibit chromosomal abnormalities. Specific cytogenetic aberrations often are predictors of outcome, especially in hematologic neoplasms, such as monosomy 7 in myeloid malignancies. The functional consequences of aneuploidy at the cellular level are difficult to assess because of a lack of convenient markers to distinguish abnormal from diploid cells. We performed single-cell RNA sequencing (scRNA-seq) to study hematopoietic stem and progenitor cells from the bone marrow of 4 healthy donors and 5 patients with bone marrow failure and chromosome gain or loss. In total, transcriptome sequences were obtained from 391 control cells and 588 cells from patients. We characterized normal hematopoiesis as binary differentiation from stem cells to erythroid and myeloid-lymphoid pathways. Aneuploid cells were distinguished from diploid cells in patient samples by computational analyses of read fractions and gene expression of individual chromosomes. We confirmed assignment of aneuploidy to individual cells quantitatively, by copy-number variation, and qualitatively, by loss of heterozygosity. When we projected patients' single cells onto the map of normal hematopoiesis, diverse patterns were observed, broadly reflecting clinical phenotypes. Patients' monosomy 7 cells showed downregulation of genes involved in immune response and DNA damage checkpoint and apoptosis pathways, which may contribute to the clonal expansion of monosomy 7 cells with accumulated gene mutations. scRNA-seq is a powerful technique through which to infer the functional consequences of chromosome gain and loss and explore gene targets for directed therapy.
机译:癌细胞经常表现出染色体异常。特异性细胞遗传学畸变通常是结果的预测因子,特别是在血液学肿瘤中,例如骨髓恶性肿瘤中的单体7。由于缺乏方便的标记,难以评估细胞水平在细胞水平的功能后果难以评估,以区分二倍体细胞异常。我们进行单细胞RNA测序(SCRNA-SEQ),从4个健康供体的骨髓和5例骨髓衰竭和染色体增益或损失研究造血干细胞和祖细胞。总共,从391个对照细胞和来自患者的588个细胞获得转录组序列。我们将正常的血缺陷表征为与干细胞到红细胞和骨髓淋巴结途径的二进制分化。通过读数分数和单个染色体的基因表达的计算分析,将非植物细胞与患者样品中的二倍体细胞区分开来。我们通过拷贝数变异,通过缺失杂合性来确认单倍对个体细胞的分配给个体细胞。当我们将患者的单细胞投影到正常血液血液血症的地图上时,观察到不同的模式,广泛反映临床表型。患者的单体7细胞显示出在免疫应答和DNA损伤检查点和凋亡途径中参与的基因下调,这可能有助于用累积基因突变的单体7细胞的克隆膨胀。 Scrna-SEQ是一种强大的技术,通过该技术,以推断染色体增益和损失的功能后果,探索导向治疗的基因靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号